Importantly, experiences from ongoing clinical trials in PCa, such as those evaluating PSMA‐targeted docetaxel nanoparticles (e.g., BIND‐014), have highlighted practical limitations including limited patient stratification, unexpected immune responses, and production scalability [14]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.